Evercore Cuts Boston Scientific (NYSE:BSX) Price Target to $96.00

Boston Scientific (NYSE:BSX) had its price objective lowered by Evercore from $112.00 to $96.00 in a research report sent to investors on Thursday, Marketbeat.com reports. The brokerage currently has an outperform rating on the medical equipment provider’s stock.

A number of other equities research analysts have also recently issued reports on BSX. Needham & Company LLC cut their price objective on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research note on Thursday. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Canaccord Genuity Group reduced their price objective on Boston Scientific from $131.00 to $112.00 and set a “buy” rating on the stock in a research note on Thursday. Morgan Stanley lowered their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, Stifel Nicolaus reduced their price target on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $109.43.

Boston Scientific Trading Down 1.8%

Shares of BSX stock opened at $76.24 on Thursday. The business has a 50-day moving average price of $93.39 and a two-hundred day moving average price of $98.75. Boston Scientific has a 12-month low of $74.86 and a 12-month high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm has a market cap of $113.02 billion, a P/E ratio of 39.30, a price-to-earnings-growth ratio of 1.35 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts anticipate that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the stock. Steph & Co. purchased a new position in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. purchased a new stake in Boston Scientific in the third quarter worth $25,000. Murphy & Mullick Capital Management Corp grew its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC bought a new position in Boston Scientific in the second quarter worth $26,000. Finally, United Community Bank lifted its position in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation
• Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note
• Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure
• Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity
• Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness
• Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigation Frank R. Cruz investigation
• Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note 12-month low report
• Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.